Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.67 |
| ▸ | CA1 | P00915 | 5/20 | 0.67 |
| ▸ | CA2 | P00918 | 5/20 | 0.67 |
| ▸ | CA9 | Q16790 | 5/20 | 0.67 |
| ▸ | SUCNR1 | Q9BXA5 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21068676 | 0.96 | CA12 (0.66) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL3174253 | 0.88 | CA1 (0.53) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL24920672 | 0.87 | CA12 (0.67) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL917117 | 0.87 | CA1 (0.54) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL14811632 | 0.86 | CA12 (0.64) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL7488414 | 0.86 | CA12 (0.67) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL15672693 | 0.86 | CA12 (0.70) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL4459617 | 0.85 | CA12 (0.65) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL4427701 | 0.85 | PTPN1 (0.52) | CA12CA1CA2CA9SUCNR1 | |
| SCHEMBL15894974 | 0.84 | CA12 (0.68) | CA12CA1CA2CA9SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108529-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
| WO-2010132852-A2 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108529-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | CA12 2693/4885CA1 943/4885CA2 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.